Abstract
Although early studies observed that peritoneal membrane transport characteristics were determinants of morbidity and mortality in peritoneal dialysis (PD) patients, more recent investigations, such as the Ademex trial, have refuted these findings. The aim of this study was to determine whether baseline peritoneal transport status predicted subsequent survival in Australian and New Zealand PD patients. The study included all adult patients in Australia and New Zealand who commenced PD between April 1, 1999, and March 31, 2004, and had a peritoneal equilibration test (PET) performed within 6 mo of PD commencement. Times to death and death-censored technique failure were examined by Kaplan-Meier analyses and multivariate Cox proportional hazards models. PET measurements were available in 3702 (72%) of the 5170 individuals who began PD treatment in Australia or New Zealand during the study period. In these patients, high transporter status was found to be a significant, independent predictor of death-censored technique failure (adjusted hazard ratio [AHR] 1.23; 95% confidence interval [CI] 1.02 to 1.49; P = 0.03) and mortality (AHR 1.34; 95% CI 1.05 to 1.79, P = 0.02) compared with low-average transport status. High-average transport class was also associated with mortality (AHR 1.21; 95% CI 1.00 to 1.48; P = 0.047) but not death-censored technique failure (AHR 1.04; 95% CI 0.90 to 1.21) compared with low-average transport status. When transport status was alternatively analyzed as a continuous variable, dialysate:plasma creatinine ratio at 4 h was independently predictive of both death-censored technique failure (AHR 1.07; 95% CI 1.01 to 1.295; P = 0.031) and death (AHR 1.09; 95% CI 1.01 to 1.373; P = 0.036 per 0.1 change in dialysate:plasma creatinine). Peritoneal transport rate is a highly significant risk factor for both mortality and death-censored technique failure in the Australian and New Zealand incident PD patient populations.
Peritoneal permeability, as assessed by the dialysate:plasma creatinine ratio from a peritoneal equilibration test (PET) (1), varies widely between peritoneal dialysis (PD) patients and has been found to differ significantly between distinct populations (2,3). Higher peritoneal transport status has been shown to be associated with a number of mortality and technique failure risk factors, including age, racial origin, body mass index, comorbid illness burden, hypoalbuminemia, and elevated inflammatory markers (2,4–6). However, it is presently unclear whether peritoneal transport status per se is an independent risk factor for morbidity and mortality in PD patients. Although early studies observed that peritoneal membrane transport characteristics were important determinants of morbidity and mortality in PD patients (6–17), more recent investigations, such as the Ademex trial (18), have not confirmed these findings (18–21). The reasons for these conflicting observations are not clear, although many of the published studies to date have suffered from a number of serious limitations, including small sample sizes, relatively short follow-up durations, low numbers of events, restriction of observations to single centers, highly selected patient populations, or the inclusion of prevalent patients (thereby potentially introducing informative censoring bias). The aim of our study was to determine whether baseline peritoneal transport status predicted subsequent survival in a large cohort of Australian and New Zealand PD patients using PET data obtained from the Australian and New Zealand Dialysis and Transplant Association (ANZDATA) Registry.
Materials and Methods
Study Population
Our analysis included all patients in Australia and New Zealand who commenced PD between April 1, 1999, and March31, 2004; were older then 18 yr; and had a PET performed within the first 6 mo of PD commencement. These patients were followed until cessation of PD; death; or March 31, 2004.
Full details regarding the structure and the methods of the ANZDATA Registry are reported elsewhere (22). In summary, the collection is complete from the first renal replacement therapy in Australasia in 1963 and includes all patients from all renal units in both countries. The data collected consist of information about the underlying cause of ESRD, demographic details, a limited range of comorbidities (the presence of coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, hypertension, and smoking), the type and dose of dialysis treatment, details about renal transplantation and measurements of height and (from 1 April 1999) dialysate:plasma creatinine ratio at 4 h (D:P Cr 4 h).
Peritoneal transport status was considered both as a continuous variable (D:P Cr 4 h) and as a categorical variable, according to the four groupings of D:P Cr 4 h values defined by Twardowski (low <0.50, low-average 0.50 to 0.64, high-average 0.65 to 0.80, and high ≥0.81) (1). Baseline D:P Cr, weekly peritoneal Kt/V, and residual renal function were collected once for each patient within the first 6 mo of PD commencement (usually at 1 mo). For potentially related comorbidities, “suspected” was combined with “yes” for analyses. Body mass index (BMI) was calculated from the height and dry weight (empty of dialysis fluid) at commencement of PD and analyzed as either a categorical variable according to World Health Organization criteria (obese ≥30 kg/m2, overweight 25 to 30 kg/m2, normal weight 18.5 to 24.99 kg/m2, and underweight <18.5 kg/m2) or as a continuous variable, where indicated.
Statistical Analyses
Results are expressed as mean ± SD for continuous data and as frequencies and percentages for categorical data. Differences in D:P Cr 4 h between PD patient subgroups were evaluated by unpaired t test or ANOVA. The distributions of categorical variables across each of the four transport groups were compared using the χ2 test. Survival curves, survival probabilities, and estimated mean survival times were generated according to the Kaplan-Meier method. Survival analyses were also performed using univariate and multivariate Cox proportional hazards models using enter method and backward stepwise elimination based on the likelihood ratio. The covariates included in the Cox models were peritoneal transport category; age; gender; racial origin; smoking status; BMI category; weekly peritoneal Kt/V; residual renal function; vintage year; PD modality; and the presence or absence of hypertension, chronic lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease, and diabetes. Data were censored at the time of renal transplantation; March 31, 2004; or 60 d after transfer to hemodialysis for the overall survival analyses, whereas the death-censored technique analyses were censored at the time of renal transplantation; death; or March 31, 2004. Adjusted survival curves were estimated using the Cox average covariate method, which calculates predicted survival probabilities at the mean levels of the covariates. Proportional hazards assumptions were checked by Schoenfeld residuals and scaled Schoenfeld residuals, examined by formal hypothesis test and graphically. First-order interaction terms between the significant covariates were examined for all models. Additional subgroup survival analyses were performed in the automated peritoneal dialysis (APD) and continuous ambulatory PD (CAPD) populations. Data were analyzed using the software package SPSS for Windows release 11.5 (SPSS Inc., North Sydney, Australia). P < 0.05 were considered statistically significant.
Results
Baseline Characteristics
Baseline D:P Cr 4 h measurements were available in 3702 (72%) of the 5170 individuals who began PD treatment in Australia or New Zealand between April 1, 1999, and March 31, 2004. Compared with the 1468 patients who did not have a D:P Cr 4 h measurement available for study, those who did were significantly younger and had a higher mean weekly peritoneal Kt/V but were less likely to have lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease, and diabetes (Table 1). Only those people with D:P Cr 4 h measurements were considered for further analysis of the impact of baseline peritoneal transport characteristics on PD outcomes.
Comparison of the baseline characteristics of incident Australian and New Zealand PD patients who did or did not have D:P Cr 4 h measurements performed in the first 6 mo of dialysis onseta
The main baseline demographic and clinical characteristics of the study population are presented in Table 2 (mean ± SD age 59.4 ± 14.8 yr, 54% male, 38% diabetic, 70% white). The mean D:P Cr 4 h was 0.69 ± 0.12, and the numbers of high, high-average, low-average, and low transporters were 614 (16.6%), 1848 (49.9%), 1055 (28.5%), and 185 (5.0%), respectively (Figure 1). Compared with low and low-average transporters, high and high-average transport categories had lower mean BMI, were more likely to be male, and were more likely to be treated with APD (Table 2). Racial origin varied significantly between each of the peritoneal transport groups; in particular, Asians seemed to have a lower peritoneal transport status.
Distribution of baseline peritoneal equilibration test (PET) measurements in the study population. The mean ± SD dialysate:plasma creatinine ratio at 4 h (D:P Cr 4 h) was 0.69 ± 0.12. L, low; LA, low-average; HA, high-average; H, high transport classes according to the definitions by Twardowski.
Baseline characteristics of the study population (n = 3702)a
By the end of the study, 1632 (44.1%) patients were alive on PD, 1074 (29.0%) transferred to hemodialysis, 298 (8.0%) had received a transplant, 36 (1.0%) spontaneously recovered renal function and ceased dialysis, four (0.1%) were lost to follow-up, and 688 (18.6%) had died. A total of 1231 (33.3%) individuals received APD treatment at some point during the study period.
Death-Censored Technique Survival
The median actuarial death-censored technique survival for the overall population was 3.7 yr (95% confidence interval [CI] 3.4 to 4.0 yr). The causes of technique failure among the study cohort were reported as patient preference (35%), followed by inadequate solute clearance (19%), acute peritonitis (11%), recurrent peritonitis (9%), and inadequate fluid clearance (9%). Transport class was not significantly associated with death-censored technique survival on either univariate Cox regression analysis (Table 3) or Kaplan-Meier analysis (log rank 5.49; P = 0.14). However, after multivariate Cox proportional hazards model analysis, high transporter status was a significant, independent predictor of death-censored technique failure (Table 3, Figure 2). The other independent predictors of death-censored technique failure were overweight or obese BMI. Conversely, Maori/Pacific Islander racial origin, Asian racial origin, higher baseline weekly peritoneal Kt/V, and higher baseline residual renal function were associated with improved death-censored technique survival. These results were consistent between the uni- and multivariate analyses. When peritoneal membrane permeability was alternatively analyzed as a continuous variable, D:P Cr 4 h remained a strong, independent predictor of death-censored technique failure (adjusted hazard ratio [HR] 1.08; 95% CI 1.01 to 1.295; P = 0.031) per 0.1 change in D:P Cr 4 h. Subgroup analyses according to type of PD therapy prescribed demonstrated that high transporter status was independently predictive of death-censored technique failure for patients who received CAPD (adjusted HR 1.43; 95% CI 1.12 to 1.81; P < 0.01) but not for those who received APD (adjusted HR 0.98; 95% CI 0.71 to 1.36; P = 0.91). No significant first-order interactions were identified between peritoneal transport status and other covariates (including BMI).
Multivariate Cox-adjusted death-censored technique survival curves for each of the four peritoneal transport classes.
Predictors of death-censored technique survival in 3702 incident PD patients in Australia and New Zealand, based on the results of univariate and multivariate Cox regression analysesa
Overall Survival
A total of 688 (18.6%) patients died during the study period. The causes of death were cardiovascular disease (58%), withdrawal from dialysis (16%), infection (14%), malignancy (4%), cachexia (2%), perforated abdominal viscus (1%), and other (5%). Median actuarial patient survival for the whole study population was 4.3 yr (95% CI 3.9 to 4.6 yr) but was significantly shorter for high transporters (3.6 yr; 95% CI 3.3 to 3.9 yr) than for the remaining three transport classes (log rank 9.56; P = 0.023). Compared with low-average transporters, mortality was significantly increased in high transporters (HR 1.43; 95% CI 1.14 to 1.80; P = 0.002), with a similar trend in high-average transporters (HR 1.20; 95% CI 0.99 to 1.45; P = 0.05) in univariate Cox proportional hazards model analyses (Table 4). After multivariate adjustment, mortality rates were significantly increased in both high-average (adjusted HR 1.21; 95% CI 1.00 to 1.48; P = 0.05) and high transport classes (adjusted HR 1.34; 95% CI 1.05 to 1.79; P = 0.02; Table 4, Figure 3). Mortality was also independently predicted by higher age, Aboriginal and Torres Strait Islander racial origin, BMI <18.5 kg/m2, coronary artery disease, peripheral vascular disease, cerebrovascular disease, diabetes, and requirement for antihypertensive treatment. Conversely, Asian racial origin, higher baseline peritoneal Kt/V, and higher baseline residual renal function were associated with enhanced survival. When peritoneal membrane permeability was alternatively analyzed as a continuous variable, D:P Cr 4 h remained a strong, independent predictor of mortality (adjusted HR 1.098; 95% CI 1.01 to 1.373; P = 0.036) per 0.1 change in D:P Cr 4 h.
Multivariate Cox-adjusted survival curves for each of the four peritoneal transport classes.
Predictors of survival in 3702 incident PD patients in Australia and New Zealand, based on the results of univariate and multivariate Cox regression analyses
Cox multivariate analysis, with backward stepwise elimination based on the likelihood ratio, did not alter the strong associations between peritoneal transport status and death-censored technique survival and overall survival (data not shown). Subgroup analyses according to type of PD therapy prescribed demonstrated that high transporter status was independently predictive of mortality for patients who received CAPD (adjusted HR 1.44; 95% CI 1.08 to 1.93; P = 0.01) but not for those who received APD (adjusted HR 1.39; 95% CI 0.87 to 2.21; P = 0.16). No significant first-order interactions were identified between peritoneal transport status and other covariates (including BMI).
Discussion
This study demonstrated that peritoneal transport status is a highly significant risk factor for both mortality and death-censored technique failure in the Australian and New Zealand incident PD patient populations. This risk is independent of demographic characteristics, BMI, comorbid clinical illnesses, peritoneal small solute clearances, and residual renal function. Moreover, peritoneal permeability remains a risk factor for adverse PD outcomes regardless of whether it is analyzed as a continuous or a categorical variable.
Our study is by far the largest examination to date of the relationship between peritoneal transport rate and PD outcomes. Its findings are in keeping with those of a number of earlier investigations (6–17). For example, in an analysis of the CANUSA data, Churchill et al. (7) demonstrated that the relative risk of either technique failure or death was increased by 19% (95% CI 5 to 34%) for each 0.1 increase in D:P Cr 4 h. Two-year survival probabilities of high, high-average, low-average, and low transporters were 70.5, 72.4, 80.4, and 90.9%, respectively (P = 0.11). The 2-yr probabilities of both patient and technique survival were 48, 52, 61, and 86%, respectively (P = 0.006). These results were observed despite that small solute clearances were greater (although not significantly) with higher transport status. Fried et al. (10) similarly demonstrated in a prospective study of 123 PD patients that the respective 3-yr survival probabilities of high, high-average, low-average, and low transporters were 70.5, 90.9, 88.9, and 100% (P < 0.05), despite no significant differences observed in small solute clearance between the groups. Davies et al. (11) prospectively analyzed survival in 210 and subsequently 303 (6) consecutive PD patients using Cox proportional hazards models and identified that a high D:P Cr 4 h was an independent predictor of death. Similar results were reported by Wu et al. (17), Wang et al. (8), Hung et al. (13), and Cueto-Manzano et al. (16) in population sizes ranging between 46 and 171.
More recent studies, however, have failed to observe an independent relationship between peritoneal permeability and PD outcomes (18–21). The largest and best known of these investigations was the ADEMEX trial (18), which observed no significant effect of baseline peritoneal transport characteristics (as determined by the dialysis adequacy and transport test) on the survival of 965 PD patients. The apparent disparity in findings may be explained by the fact that the ADEMEX trial assessed peritoneal transport status by the dialysis adequacy and transport test (which may have given different results compared with PET) and predominantly included prevalent patients, thereby potentially introducing informative censoring bias. For example, if high transport status is associated with a higher technique failure rate, then this group may have been underrepresented in a study of prevalent PD patients. Moreover, in contrast to our study, which examined the vast majority of Australian and New Zealand PD patients, the ADEMEX trial included only a fraction of the total PD population of 24 dialysis centers in Mexico, thereby raising the possibility of ascertainment and selection biases.
Similarly, the prospective, multicenter European Automated PD Outcome Study found that baseline D:P Cr 4 h had no effect on overall or technique survival in 177 patients (19). However, the results may have been adversely affected by the preferential selection of anuric, prevalent automated PD patients and by the relatively low number (n = 31) of deaths (thereby making a possible type 2 statistical error likely). Other negative studies (12,20,21) likewise have been limited by small sample sizes (≤213 patients), short follow-up times, low event rates, and restriction to single-center observations.
A significant change in the use of automated PD was observed in our study during the data collection period between April 1999 and March 2004. In 1999, 11.4% of all patients who were treated with PD in Australia and New Zealand received automated PD treatment. By 2003, the percentage had risen to 27.7%. However, when the proportion of patients who were being treated with automated PD and the year in which patients received PD were included as covariates in the Cox regression analyses, strong associations were still observed between peritoneal transport status and both death-censored technique survival and overall survival. When subgroup analyses were performed according to the type of PD therapy prescribed, high transporter status was independently predictive of death-censored technique failure and mortality for patients who were receiving CAPD but not for those who were receiving APD. Although a type 2 statistical error in the APD subgroup analysis could not be excluded, it is also possible that APD therapy abrogated the deleterious clinical consequences of high peritoneal transport rate.
There is also a possibility that racial differences influenced the relationship between peritoneal transport and outcomes. For example, a recent study by Chung et al. (9) observed that D:P Cr 4 h was an independent predictor of mortality in 136 Korean PD patients but not in 106 Swedish PD patients. These differences, however, also may have been attributable to differential access to icodextrin therapy, center effects (because they involved only one center in Korea and another in Sweden), differences in PET protocols (4.25 versus 2.27% glucose solutions), informative censoring bias as a result of a much higher transplantation rate in the Swedish center, and inadequate statistical power.
The exact mechanisms for the poorer survival of high and high-average transporters in our study remain unclear but may relate at least partially to impaired ultrafiltration and fluid overload (8,12,21,23,24). High peritoneal transport is associated with a more rapid absorption of glucose and hence dissipation of the osmotic gradient required for sustained ultrafiltration. There is evidence that patients with symptomatic fluid retention are 3.7 times more likely to be high than low transporters (25). The finding in our study that high peritoneal transport status was not associated with death-censored technique survival and overall survival in the subgroup of patients who were receiving APD therapy may have reflected better fluid control with this PD modality. It has also been argued that the increased mortality of high transporters is primarily due to an association between D:P Cr 4 h and comorbid illness burden (6). Chung et al. (15) reported that high transport status was an independent risk factor for mortality in patients with comorbid disease but not in those without comorbidity. However, this may have been due to a low event rate (and therefore inadequate statistical power) in the latter group, because our study did not replicate these findings and because we have previously reported a lack of significant association between D:P Cr 4 h and comorbid disease (2).
Malnutrition may also have contributed to the excess mortality in high transporters, because such patients have a higher prevalence of hypoalbuminemia (5,7,8,16,26–29). A low serum albumin correlates with other markers of malnutrition, such as normalized protein catabolic rate and subjective global assessment (30), and is strongly predictive of PD patient death (31,32). Nolph et al. (33) and Kang et al. (27) demonstrated that high peritoneal permeability was associated with a reduced normalized protein catabolic rate and composite nutritional index, but these associations were not confirmed by the CANUSA study (7). The greater prevalence of hypoalbuminemia in high transporters may also arise from hemodilution secondary to suboptimal ultrafiltration (34) or from excessive peritoneal protein losses (28). Alternatively, hypoalbuminemia in high transporters may reflect a greater incidence of underlying chronic inflammation (12,35), although other studies have not observed a significant correlation between D:P Cr 4 h and various inflammatory markers, such as C-reactive protein (4,36).
The strengths of this study included its very large sample size and the robustness of its findings across different statistical methods. Because we included all centers across both countries, the external validity of our findings was greatly enhanced. Moreover, our cohort consisted solely of incident patients, thereby avoiding the potentially confounding factor of survivor bias associated with prevalent population studies.
Nevertheless, the use of registry data in this article also carried significant limitations. Because of the retrospective nature of the analysis and that only 72% of the entire cohort had baseline PET results, the potentials for both recall and selection biases were present. As shown in Table 1, patients with certain characteristics were more likely to have undergone a D:P Cr 4 h measurement during the study period. Although these differences were statistically significant, the actual sizes of the differences were generally minor. Furthermore, ANZDATA does not collect information on drain volume, nutritional markers (e.g., albumin), inflammatory markers, icodextrin therapy, or the severity of comorbidities, so residual confounding or unidentified associations could not be excluded entirely. In common with other registries, ANZDATA is a voluntary registry, and there is no external audit of data accuracy.
In conclusion, high peritoneal transport status is a highly significant, independent risk factor for both mortality and death-censored technique failure in the Australian and New Zealand incident PD patient populations. Further studies are required to determine whether the adverse prognosis of high transporters can be improved by various therapeutic strategies, such as automated PD, icodextrin, nutritional supplementation, anti-inflammatory therapies, or early conversion to hemodialysis.
Acknowledgments
We gratefully acknowledge the substantial contributions of the entire Australia and New Zealand nephrology community (physicians, surgeons, database managers, nurses, renal operators, and patients) in providing information for and maintaining the ANZDATA Registry database.
Footnotes
-
Published online ahead of print. Publication date available at www.jasn.org.
- © 2006 American Society of Nephrology
References
Jump to section
More in this TOC Section
Cited By...
- No citing articles found.